Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced the publication of findings from its Phase 2 SEISMiC B study on ...

Persistent high blood pressure, or resistant hypertension, requires a proactive and personalized approach beyond just ...

Istaroxime has completed four positive Phase 2 studies, including two in early cardiogenic shock (called SCAI Stage B). Market research conducted by the Company with U.S. based clinical cardiologists ...

Initially used for blood glucose control, the medications reduce cardiovascular events and mitigate heart failure ...

Patients hospitalized for severe COVID-19 exhibit cardiac systolic dysfunction and small vessel disease at long-term ...

Finerenone treatment vs placebo was associated with a reduced risk for new-onset diabetes by 24% among patients with HFmrEF or HFpEF.

A noteworthy case study. How to help a teenage girl with familial hypercholesterolemia who has chest pains and is ...

Adding This Leafy Green to Lunch Lowers Systolic Levels Fast, According to Cardiologists originally appeared on Parade.

Background Severe left ventricular (LV) systolic dysfunction is an uncommon complication of hypertrophic cardiomyopathy (HCM) that is associated with poor prognosis. Small observational series suggest ...

The natural history of subclinical systolic and diastolic LV dysfunction in the general population is currently unknown. Serial imaging studies are required to clarify the progression of LV ...

– For people who have heart failure with a normal heart rhythm, there seems to be little to no advantage of warfarin (an anticoagulant: a medicine which prevents blood clotting by blocking proteins) ...

Mydicar is under clinical development by Sardocor and currently in Phase II for Systolic Heart Failure. According to GlobalData, Phase II drugs for Systolic Heart Failure have a 67% phase transition ...